Nautilus Biotechnology, Inc. is a life sciences company, which engages in the development of a proteomics platform for analyzing and quantifying the human proteome. Its products include Proteome Analysis System, Reagent Kits, and Software and Analysis. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Nautilus Biotechnology published a peer-reviewed study in Nature Methods demonstrating its Iterative Mapping technology for large-scale, single-molecule analysis of intact tau proteoforms. - The Nautilus Tau Proteoforms Assay resolved 130 tau proteoform groups from up to 768 biologically feasible groups, quantifying proteoforms present at just 0.1% of a sample with a median coefficient of variation below 5.5%. - Researchers found tau modifications accumulate in ordered, non-random sequences, and the most severely affected Alzheimer's patient carried the most heavily phosphorylated tau, including a 1N3R proteoform with four phosphorylation sites. - The findings may support discovery of new biomarkers and drug targets for Alzheimer's disease and related tauopathies, with the assay now available through Nautilus' Iterative Mapping Early Access Program.
- Nautilus Biotechnology (NASDAQ: NAUT) will release its Q2 2026 financial results before market open on Tuesday, July 28, 2026. - Management will host a conference call and webcast at 5:30 a.m. PT / 8:30 a.m. ET to discuss results, business developments, and outlook. - The company is pioneering a single-molecule protein analysis platform aimed at transforming proteomics and enabling advances in human health. - Nautilus remains a development-stage life sciences company with dual headquarters in Seattle, Washington and San Carlos, California.
- Nautilus Biotechnology has launched an Early Access Program for its novel single-molecule proteomics platform, featuring a tau proteoforms assay as the first offering for exclusive researcher groups. - The platform's Iterative Mapping method enables single-molecule analysis of proteins and proteoforms, designed to achieve comprehensive proteome coverage and precisely map post-translational modifications patterns. - Researchers at the Buck Institute for Research on Aging are successfully using the platform to map up to 768 distinct tau proteoforms across brain regions, revealing disease progression patterns. - The program represents a key commercialization milestone, demonstrating the platform's readiness for external use while offering custom assay development partnerships for specific research applications.
- Nautilus Biotechnology successfully installed and tested its first external field evaluation unit at the Buck Institute for Research on Aging, marking a critical milestone for single-molecule proteomics platform deployment. - The collaboration generated highly reproducible tau proteoform data from neurodegenerative disease samples over six months, providing external validation of the company's next-generation proteomics technology. - The proprietary tau proteoform assay can quantify 768 proteoform groups, enabling unprecedented analysis of protein modifications that influence Alzheimer's disease progression. - Initial findings will be presented at the 2025 HUPO World Congress, demonstrating the platform's potential to advance understanding of complex disease biology and neurodegeneration mechanisms.
- Nautilus Biotechnology has entered into an agreement with the Allen Institute to investigate the connection between tau protein and Alzheimer's disease using single-molecule proteomics technology. - The collaboration will employ Nautilus' Iterative Mapping method to identify novel tau proteoforms from human brain tissue and characterize phosphorylation patterns that may predict disease progression. - Nautilus' recent preprint demonstrates the platform's ability to analyze millions to billions of single-protein molecules with unprecedented resolution, providing actionable biological insights from brain samples of cognitively normal and impaired Alzheimer's patients.
- Amazon disclosed a $14.7 million investment in Nautilus Biotechnology, a pre-revenue company developing proteome measurement technology for drug discovery and clinical diagnostics. - Nautilus has built a prototype device that aims to measure more than 95% of the human proteome, compared to current mass spectrometers that only capture a small percentage of proteins. - The investment represents Amazon's continued expansion into healthcare following its $753 million PillPack acquisition and development of Amazon Care telehealth services. - Nautilus expects its first revenue in 2022 and has partnered with Roche-owned Genentech to use its proteome analysis system for research applications.
